New guidance from a consortium of Chinese pediatric specialists aims to transform the approach to nocturnal enuresis (NE), commonly known as bedwetting, in school-age children. The updated consensus, published in the World Journal of Pediatrics, offers a practical roadmap with 18 recommendations spanning diagnosis, classification, evaluation, first-line therapy, comorbidity management, and referral pathways. This framework is designed to help clinicians move from symptom-based treatment toward more standardized, individualized, and family-centered care.
The importance of this update lies in its potential to improve outcomes for millions of children. Nocturnal enuresis is common, affecting a significant number of children aged five and older. It is more than a nighttime inconvenience; persistent bedwetting can affect self-esteem, sleep, family life, and social functioning. Effective treatments exist, yet underdiagnosis, inconsistent clinical practice, and poor adherence have limited outcomes. In China, regional differences in access, cultural perceptions, and uneven coordination between primary and specialist services further complicate care.
Since the previous Chinese consensus was issued in 2014, international standards and the evidence base have evolved substantially. The updated framework, authored by researchers from the Department of Nephrology, Children's Hospital of Fudan University, National Children's Medical Center, along with the Chinese Cooperative Group for the Management of Pediatric NE and the Pediatric Nephrology Committee of the Chinese Medical Doctor Association, reflects these changes. The consensus lowers the diagnostic threshold: children aged five years or older who experience at least one involuntary nighttime void per month for three months now qualify for diagnosis, a shift from the previous weekly standard. This change enables earlier intervention.
A critical update is the mandatory distinction between monosymptomatic NE (MNE), where no daytime lower urinary tract symptoms (LUTS) are present, and non-monosymptomatic NE (NMNE), which includes daytime symptoms like urgency, frequency, or incontinence. This classification drives all subsequent treatment decisions. The voiding diary becomes a diagnostic cornerstone, requiring patients to record at least two daytime charts and seven consecutive nights of fluid intake and voids. This allows clinicians to phenotype children as having nocturnal polyuria, reduced bladder capacity, or both.
For MNE, the consensus specifies phenotype-driven first-line therapy: desmopressin for nocturnal polyuria and the enuresis alarm for reduced bladder capacity, with combination therapy for mixed types. For NMNE, management must prioritize daytime LUTS and comorbidities—especially constipation, which affects 36–80% of these children—before addressing nighttime wetting. The framework also outlines clear referral criteria: primary care may manage MNE, but non-responders or suspected NMNE require specialist evaluation with urodynamics and lumbosacral magnetic resonance imaging (MRI). For refractory cases, defined as less than 50% improvement after three months, the consensus advises systematic re-evaluation of adherence, diary findings, and underlying causes before escalating treatment.
The authors stress that NE should not be managed as a single, uniform disorder. They emphasize identifying the child's specific pattern, looking for daytime symptoms and comorbidities, and matching treatment to the likely underlying mechanism while keeping the family involved. Apparent treatment failure should trigger a careful review—of adherence, voiding records, and possible missed conditions—before stronger or more complex therapy is added.
In practice, these recommendations could help pediatricians and primary-care clinicians identify children who can be managed locally and those needing specialist assessment. Clearer use of voiding diaries and symptom-based classification may reduce trial-and-error treatment, while earlier attention to constipation, sleep-disordered breathing, attention-deficit/hyperactivity disorder (ADHD), and daytime urinary symptoms could improve response rates. The framework also encourages timely referral when first-line therapy fails or NMNE is suspected, supporting better coordination across levels of care.
While some recommendations reflect Chinese practice patterns and evidence remains limited for areas such as desmopressin withdrawal strategies, future trials and multidisciplinary care models could further refine individualized treatment. The full guidance is available in the World Journal of Pediatrics (DOI:10.1007/s12519-026-01051-4), with the original source at https://doi.org/10.1007/s12519-026-01051-4.
